1.50432
LiChrosorb® RP-8 (5 µm) HPLC Columns
L x I.D. 125 mm x 4 mm, Hibar® RT HPLC Column
別名:
TM=["LiChrosorb"] C8 HPLC column
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
UNSPSC Code:
41115709
NACRES:
SB.52
Particle size:
5 μm
Matrix active group:
C8 (RP8), C8 bonding phase
Pore size:
100 Å pore size
Matrix:
fully porous particle
製品名
LiChrosorb® RP-8 (5 µm) Hibar® RT 125-4, suitable for HPLC
material
stainless steel column
Quality Segment
agency
suitable for USP L7
product line
LiChrosorb®
feature
endcapped: no
parameter
400 bar pressure, 60 °C max. temp.
technique(s)
HPLC: suitable, mass spectrometry (MS): suitable (Low)
column L × I.D.
12.5 cm × 4 mm
matrix
fully porous particle
matrix active group
C8 (RP8), C8 bonding phase
particle size
5 μm
pore size
100 Å pore size
operating pH range
2-7.5
separation technique
reversed phase, supercritical fluid (SFC)
storage temp.
no temp limit
General description
HPLC column
LiChrosorb® RP-8 is a reliable irregular shaped silica gel carriers with reversed phase properties. It is well suited for the separation of neutral, acidic and weak basic compounds.This sorbent is packed into a Hibar
Application
- Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography.: This study by Egger et al. focuses on the HPLC determination of various forms of amphotericin B in plasma, utilizing LiChrosorb® RP-8 as the stationary phase. This method ensures accurate monitoring of these antifungal agents in clinical settings (Egger et al., 2001).
- Determination of peptide hydrophobicity parameters by reversed-phase high-performance liquid chromatography.: This research by Rothemund et al. used LiChrosorb® RP-8 to determine the hydrophobicity of various peptides, providing valuable insights for peptide characterization in biochemical research (Rothemund et al., 1994).
- HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.: Beijnen et al. employed LiChrosorb® RP-8 in an HPLC method to quantify doxorubicin and its metabolites in plasma, offering a robust tool for therapeutic drug monitoring in AIDS patients (Beijnen et al., 1991).
Analysis Note
Pressure: ≤ 50 bar
Theoretical Plates (N/m) (Toluene): ≥ 55000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 0.5 - 1.5
Theoretical Plates (N/m) (Toluene): ≥ 55000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 0.5 - 1.5
Legal Information
Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany
LiChrosorb is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under LiChrosorb® RP-8 (5 µm) Hibar® RT 125-4